UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
32.10
+2.31 (7.75%)
Nov 19, 2026, 1:58 PM EST - Market open
UroGen Pharma Revenue
UroGen Pharma had revenue of $89.00M in the quarter ending September 30, 2026, with 223.85% growth. This brings the company's total for the last twelve months to $250.25M, up 159.29% year-over-year. In the year 2025, UroGen Pharma had annual revenue of $109.79M with 21.45% growth. That makes UroGen Pharma the 15,861st largest company in the world by revenue and 2,728th in the United States.
Revenue (ttm)
$250.25M
Revenue Growth
+159.29%
P/S Ratio
5.84
Revenue / Employee
$834,177
Employees
300
Market Cap
1.57B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 109.79M | 19.39M | 21.45% |
| Dec 31, 2024 | 90.40M | 7.69M | 9.29% |
| Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
| Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
| Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
| Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
| Dec 31, 2019 | 18.00K | -1.11M | -98.40% |
| Dec 31, 2018 | 1.13M | -7.03M | -86.17% |
| Dec 31, 2017 | 8.16M | -9.37M | -53.46% |
| Dec 31, 2016 | 17.53M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nurix Therapeutics | 701.94M |
| Immunocore Holdings | 429.30M |
| Nuvation Bio | 201.73M |
| Precigen | 156.94M |
| uniQure | 20.17M |
| ADARx Pharmaceuticals | 6.13M |
URGN News
- 9 days ago - UroGen Pharma Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 14 days ago - UroGen Pharma price target lowered to $62 from $65 at Ladenburg - TheFly
- 14 days ago - UroGen Pharma price target lowered to $56 from $58 at Guggenheim - TheFly
- 15 days ago - UroGen Pharma Earnings Call Transcript: Q3 2026 - Transcripts
- 15 days ago - UroGen Pharma Earnings release: Q3 2026 - Filings
- 15 days ago - UroGen Pharma Quarterly report: Q3 2026 - Filings
- 15 days ago - UroGen Pharma reports Q3 EPS (3c), consensus 10c - TheFly
- 15 days ago - UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights - GlobeNewsWire